NASDAQ:XBIT - XBiotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.08 -0.16 (-1.73 %) (As of 05/19/2019 04:00 PM ET)Previous Close$9.08Today's Range$9.07 - $9.6652-Week Range$2.13 - $11.74Volume90,880 shsAverage Volume89,461 shsMarket Capitalization$327.88 millionP/E RatioN/ADividend YieldN/ABeta0.25 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection and influenza diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas. Receive XBIT News and Ratings via Email Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XBIT Previous Symbol CUSIPN/A CIK1626878 Webwww.xbiotech.com Phone512-386-2900Debt Debt-to-Equity RatioN/A Current Ratio4.57 Quick Ratio4.57Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book8.90Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-21,140,000.00 Net MarginsN/A Return on Equity-51.88% Return on Assets-48.82%Miscellaneous Employees56 Outstanding Shares36,110,000Market Cap$327.88 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable XBiotech (NASDAQ:XBIT) Frequently Asked Questions What is XBiotech's stock symbol? XBiotech trades on the NASDAQ under the ticker symbol "XBIT." When is XBiotech's next earnings date? XBiotech is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for XBiotech. Has XBiotech been receiving favorable news coverage? Media stories about XBIT stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. XBiotech earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Who are some of XBiotech's key competitors? Some companies that are related to XBiotech include Opko Health (OPK), Aimmune Therapeutics (AIMT), Corcept Therapeutics (CORT), Mallinckrodt (MNK), Phibro Animal Health (PAHC), Theravance Biopharma (TBPH), Apellis Pharmaceuticals (APLS), Epizyme (EPZM), Ra Pharmaceuticals (RARX), Inflarx (IFRX), Amphastar Pharmaceuticals (AMPH), Turning Point Therapeutics (TPTX), Clementia Pharmaceuticals (CMTA), Eidos Therapeutics (EIDX) and Homology Medicines (FIXX). What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Zynerba Pharmaceuticals (ZYNE), Amicus Therapeutics (FOLD), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD), Amarin (AMRN), Fate Therapeutics (FATE), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Strongbridge Biopharma (SBBP) and T2 Biosystems (TTOO). Who are XBiotech's key executives? XBiotech's management team includes the folowing people: Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board When did XBiotech IPO? (XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO. Who are XBiotech's major shareholders? XBiotech's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.29%), Tibra Equities Europe Ltd (0.19%), Marshall Wace LLP (0.17%), ExodusPoint Capital Management LP (0.15%), BlueCrest Capital Management Ltd (0.08%) and Citigroup Inc. (0.07%). Company insiders that own XBiotech stock include Fondation Rennes, Queena Han, W Thorpe Mckenzie and W Thorpe Mckenzie. View Institutional Ownership Trends for XBiotech. Which institutional investors are buying XBiotech stock? XBIT stock was acquired by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd, Marshall Wace LLP, ExodusPoint Capital Management LP, BlueCrest Capital Management Ltd, Citigroup Inc., BlackRock Inc., Jefferies Group LLC and Birchview Capital LP. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes and W Thorpe Mckenzie. View Insider Buying and Selling for XBiotech. How do I buy shares of XBiotech? Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is XBiotech's stock price today? One share of XBIT stock can currently be purchased for approximately $9.08. How big of a company is XBiotech? XBiotech has a market capitalization of $327.88 million. XBiotech employs 56 workers across the globe. What is XBiotech's official website? The official website for XBiotech is http://www.xbiotech.com. How can I contact XBiotech? XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at https://www.amstock.com. MarketBeat Community Rating for XBiotech (NASDAQ XBIT)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 193 (Vote Outperform)Underperform Votes: 144 (Vote Underperform)Total Votes: 337MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: How is a buy-side analyst different from a sell-side analyst? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.